Filtered By:
Drug: Angiomax
Education: Study

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 49 results found since Jan 2013.

Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in high-bleeding-risk patients with acute coronary syndrome in contemporary practice
CONCLUSIONS: The treatment of bivalirudin showed better efficacy and safety as compared to UFH among patients with ACS undergoing PCI at high risk of bleeding in contemporary practice.PMID:34321166 | DOI:10.1016/j.biopha.2020.110758
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - July 29, 2021 Category: Drugs & Pharmacology Authors: Yahao Zhang Yanghui Zhang Zhiyu Liu Bin Zhang Guizhi Liu Kui Chen Source Type: research

Outcomes of systemic anticoagulation with bivalirudin for Impella 5.0
Int J Artif Organs. 2021 Jul 12:3913988211032238. doi: 10.1177/03913988211032238. Online ahead of print.ABSTRACTTemporary mechanical circulatory support (tMCS) devices are used for the management of cardiogenic shock. The Impella 5.0 (Abiomed; Danvers, MA) (IMP5) is a commonly used, surgically implanted, tMCS device that requires systemic anticoagulation and purge solution to avoid pump failure. To avoid heparin-induced thrombocytopenia (HIT) from unfractionated heparin (UFH) use, our program has explored the utility of bivalirudin (BIV) for systemic anticoagulation in IMP5. This single center, retrospective study included...
Source: The International Journal of Artificial Organs - July 12, 2021 Category: Transplant Surgery Authors: Carly Fabrizio Marissa N Levito Ryan Rivosecchi Michael Bashline Brittany Slocum Arman Kilic Catalin Toma Holt Murray Raj Ramanan Jeffrey Fowler Gavin W Hickey Edward T Horn Source Type: research

Efficacy and Safety of Bivalirudin During Percutaneous Coronary Intervention in Chronic Total Occlusion: A Retrospective Study
The objective of this study was to examine the efficacy and safety of bivalirudin during percutaneous coronary intervention (PCI) in patients with CTO.METHODS: This trial used a retrospective cohort study design. Medical information from 736 patients with CTO who underwent PCI with bivalirudin or UFH at the First Affiliated Hospital of Zhengzhou University from July 2019 to September 2020 was extracted and analyzed. The primary end point was the 30-day incidence of net adverse clinical events (NACEs), and the secondary end point was the major adverse cardiovascular events (MACEs), which were related to safety and efficacy,...
Source: Clinical Therapeutics - April 3, 2021 Category: Drugs & Pharmacology Authors: Yanghui Zhang Yahao Zhang Chao Chang Shumei Yan Zheng Chen Lishuai Zhang Kui Chen Guizhi Liu Source Type: research

Bivalirudin in patients undergoing percutaneous coronary intervention and independent predictors of postoperative adverse events in these patients: A real world retrospective study
The efficacy and safety of bivalirudin in percutaneous coronary intervention (PCI) has always been a hot topic in perioperative antithrombotic therapy, but there are still some controversies. So studies are needed to provide more evidence, especially the real world study which includes patients excluded from previous RCT studys. Our study aimed to investigate these information and analyze the independent predictors of postoperative adverse events. A retrospective study enrolled 1416 patients underwent PCI in Tianjin Chest Hospital from May 2016 to October 2017. The incidence of stent-thrombosis and net clinical adverse ...
Source: Medicine - March 12, 2021 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

Patients treated with bivalirudin are still at higher risk of stent thrombosis: a comprehensive meta-analysis of randomised clinical trials of bivalirudin and heparin for percutaneous coronary interventions.
CONCLUSIONS: The advantages of bivalirudin are undoubtedly related to GPI use in the heparin arms. Bivalirudin-based regimens are more beneficial when compared with heparin and planned GPI use in terms of NACE and major bleedings; this was not observed when compared to heparin and provisional GPI use. Regardless of adjunctive GPI use, stent thrombosis episodes were significantly more common in bivalirudin-treated subjects. Therefore, the safety and economic issues may urge revision of this aspect of current clinical practice and guidelines. PMID: 29350380 [PubMed - indexed for MEDLINE]
Source: Kardiologia Polska - December 12, 2018 Category: Cardiology Authors: Grajek S, Michalak M, Gwizdała A, Araszkiewicz A, Grygier M, Hiczkiewicz J, Lesiak M Tags: Kardiol Pol Source Type: research

Bivalirudin versus heparin in patients undergoing percutaneous peripheral interventions: A systematic review and meta-analysis.
CONCLUSION: Our meta-analysis suggests that bivalirudin use for percutaneous peripheral interventions is associated with lower all-cause mortality, bleeding, and access site complications as compared to heparin. Further large randomized trials are needed to confirm the current results. PMID: 30501582 [PubMed - as supplied by publisher]
Source: Vascular - December 1, 2018 Category: Surgery Authors: Olmedo W, Villablanca PA, Sanina C, Walker J, Weinreich M, Brevik J, Avendano R, Bravo CA, Romero J, Ramakrishna H, Babaev A, Attubato M, Hernandez-Suarez DF, Cox-Alomar P, Pyo R, Krishnan P, Wiley J Tags: Vascular Source Type: research

Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial
Publication date: Available online 25 August 2018Source: The LancetAuthor(s): Marco Valgimigli, Enrico Frigoli, Sergio Leonardi, Pascal Vranckx, Martina Rothenbühler, Matteo Tebaldi, Ferdinando Varbella, Paolo Calabrò, Stefano Garducci, Paolo Rubartelli, Carlo Briguori, Giuseppe Andó, Maurizio Ferrario, Ugo Limbruno, Roberto Garbo, Paolo Sganzerla, Filippo Russo, Marco Nazzaro, Alessandro Lupi, Bernardo CorteseSummaryBackgroundThe Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox (MATRIX) programme was designed to assess the comparative safety and effectiveness of ra...
Source: The Lancet - August 25, 2018 Category: General Medicine Source Type: research

Comparison of Heparin and Bivalirudin in Patients Undergoing Orbital Atherectomy.
CONCLUSION: Both heparin and bivalirudin were safe and effective antithrombotic agents for patients who underwent orbital atherectomy. A randomized trial is needed to determine the antithrombotic agent of choice for orbital atherectomy. PMID: 29086730 [PubMed - in process]
Source: The Journal of Invasive Cardiology - November 2, 2017 Category: Cardiology Tags: J Invasive Cardiol Source Type: research

Bivalirudin versus heparin in patients undergoing percutaneous transcatheter aortic valve interventions: A systematic review and meta ‐analysis
ConclusionsIn patient undergoing aortic valve interventions, no difference was seen between the use of bivalirudin and heparin as the procedural anticoagulant agent, except for a significant lower myocardial infarction events when bivalirudin was used. Further large randomized trials are needed to confirm current results.
Source: Journal of Interventional Cardiology - August 21, 2017 Category: Cardiology Authors: Pedro A. Villablanca, Rasha Al ‐Bawardy, Divyanshu Mohananey, Carola Maraboto, Michael Weinreich, Tanush Gupta, David F. Briceno, Harish Ramakrishna Tags: ORIGINAL INVESTIGATION Source Type: research

Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Via Radial Access Anticoagulated With Bivalirudin Versus Heparin: A Report From the National Cardiovascular Data Registry
Conclusions In patients undergoing primary PCI via transradial access anticoagulated with bivalirudin or heparin, there was no difference in the composite endpoint of death, myocardial infarction, or stroke.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - June 5, 2017 Category: Cardiology Authors: Jovin, I. S., Shah, R. M., Patel, D. B., Rao, S. V., Baklanov, D. V., Moussa, I., Kennedy, K. F., Secemsky, E. A., Yeh, R. W., Kontos, M. C., Vetrovec, G. W. Tags: Coronary Source Type: research

No difference in rate of adverse cardiovascular events when comparing anticoagulants
In patients undergoing transradial primary percutaneous coronary intervention (PCI) for ST elevation myocardial infarction (STEMI), there was no significant difference in the rate of a composite of death, myocardial infarction and stroke whether they were anticoagulated with bivalirudin or unfractioned heparin, according to a study.
Source: ScienceDaily Headlines - May 17, 2017 Category: Science Source Type: news

Effect of postprocedural full ‐dose infusion of bivalirudin on acute stent thrombosis in patients with ST‐elevation myocardial infarction undergoing primary percutaneous coronary intervention: Outcomes in a large real‐world population
ConclusionPost‐PCI full‐dose bivalirudin infusion is safe and has a trend to protect against acute ST in STEMI patients undergoing primary PCI in real‐world settings.
Source: Cardiovascular Therapeutics - May 12, 2017 Category: Cardiology Authors: Heyang Wang, Zhenyang Liang, Yi Li, Bin Li, Junming Liu, Xueyi Hong, Xin Lu, Jiansheng Wu, Wei Zhao, Qiang Liu, Jian An, Linfeng Li, Fanli Pu, Qiang Ming, Yaling Han Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

Impact of pre ‐existing or new‐onset atrial fibrillation on 30‐day clinical outcomes following Transcatheter Aortic Valve Replacement: Results From The BRAVO 3 Randomized Trial
Conclusions: Prior or new‐onset AF within 30 days of transfemoral TAVR is noted in more than one‐third of patients. Despite greater baseline comorbidities than non‐AF patients, AF was not associated with greater risk of adjusted 30‐day outcomes. In the BRAVO 3 trial, early outcomes were similar regardless of anticoagulant strategy in each group. This article is protected by copyright. All rights reserved.
Source: Catheterization and Cardiovascular Interventions - May 1, 2017 Category: Cardiovascular & Thoracic Surgery Authors: Christian Hengstenberg, Jaya Chandrasekhar, Samantha Sartori, Thierry Lefevre, Ghada Mikhail, Nicolas Meneveau, Christophe Tron, Raban Jeger, Christian Kupatt, Birgit Vogel, Serdar Farhan, Sabato Sorrentino, Madhav Sharma, Clayton Snyder, Oliver Husser, P Tags: VSD ‐ Valvular and Structural Heart Diseases Source Type: research